Tamar Thompson - 27 Feb 2026 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Reporting relationship: Director
Issuer ticker: RNA
Reported as of: 27 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Feb 2026, 15:26:56 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 17 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact

Key filing fact

Tamar Thompson filed Form 4 for Avidity Biosciences, Inc. (RNA) on 27 Feb 2026.

Key facts

This page summarizes Tamar Thompson's Form 4 filing for Avidity Biosciences, Inc. (RNA).
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 27 Feb 2026, 15:26.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001839248 Primary reporting owner

Thompson Tamar

Relationship: Director
Address: C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO
Signature: /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Signature date: 27 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNA transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -6,692
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,034
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,034
Exercise price: $33.62
Footnotes: F2

RNA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -13,489
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,489
Exercise price: $39.96
Footnotes: F2

RNA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -22,000
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $12.48
Footnotes: F2

RNA transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -22,000
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $12.03
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Tamar Thompson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

Footnote F2

The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.